Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.81 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 3/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7824768 | 0.88 | NPSR1 (0.78) | NPSR1ALDH1A1KMT2AMEN1RAB9A | |
| SCHEMBL16722802 | 0.87 | NPSR1 (0.76) | NPSR1ALDH1A1KMT2AMEN1RAB9A | |
| SCHEMBL29528287 | 0.86 | NPSR1 (0.76) | NPSR1ALDH1A1KMT2AMEN1RAB9A | |
| SCHEMBL5534554 | 0.86 | NPSR1 (0.76) | NPSR1ALDH1A1KMT2AMEN1RAB9A | |
| SCHEMBL29528303 | 0.85 | NPSR1 (0.73) | NPSR1ALDH1A1KMT2AMEN1RAB9A | |
| SCHEMBL12935934 | 0.85 | NPSR1 (0.73) | NPSR1ALDH1A1KMT2AMEN1RAB9A | |
| SCHEMBL6931963 | 0.84 | KMT2A (0.60) | NPSR1ALDH1A1KMT2AMEN1TDP1 | |
| SCHEMBL1875367 | 0.84 | L3MBTL1 (0.73) | NPSR1ALDH1A1KMT2AMEN1TDP1 | |
| SCHEMBL16350809 | 0.84 | L3MBTL1 (0.72) | NPSR1ALDH1A1RAB9APOLBL3MBTL1 | |
| SCHEMBL3083596 | 0.83 | NPSR1 (0.71) | NPSR1ALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009051910-A1 | COMPOUNDS HAVING ACTIVITY IN INCREASING ION TRANSPORT BY MUTANT-CFTR AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-04-23 | — | — | WO | claimed |
| US-8389736-B2 | Compounds having activity in correcting mutant-CFTR processing and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-03-05 | — | — | US | disclosed |
| US-8389736-B2 | Compounds having activity in correcting mutant-CFTR processing and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-03-05 | — | — | US | disclosed |
| US-8389736-B2 | Compounds having activity in correcting mutant-CFTR processing and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-03-05 | — | — | US | disclosed |
| US-20130029967-A1 | Fused Imidazo [3,2 - D] Pyrazines as P13 Kinase Inhibitors | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2013-01-31 | — | — | US | disclosed |
| US-20100273839-A1 | Compounds Having Activity in Correcting Mutant-CFTR Processing and Uses Thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2010-10-28 | — | — | US | disclosed |
| US-20100273839-A1 | Compounds Having Activity in Correcting Mutant-CFTR Processing and Uses Thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2010-10-28 | — | — | US | disclosed |
| US-20100273839-A1 | Compounds Having Activity in Correcting Mutant-CFTR Processing and Uses Thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2010-10-28 | — | — | US | disclosed |
| WO-2009051910-A1 | COMPOUNDS HAVING ACTIVITY IN INCREASING ION TRANSPORT BY MUTANT-CFTR AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-04-23 | — | — | WO | disclosed |
| WO-2009051909-A1 | COMPOUNDS HAVING ACTIVITY IN CORRECTING MUTANT-CFTR CELLULAR PROCESSING AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-04-23 | — | — | WO | disclosed |
| US-7342016-B2 | Farnesyl protein transferase inhibitors as antitumor agents | SCHERING CORPORATION (US) | 2008-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130029967-A1 | Fused Imidazo [3,2 - D] Pyrazines as P13 Kinase Inhibitors | MTOR, PIK3CA, CDK2 | NPSR1 4014/4885ALDH1A1 2666/4885KMT2A 1289/4885 |
| US-20100273839-A1 | Compounds Having Activity in Correcting Mutant-CFTR Processing and Uses Thereof | CFTR, ABCC5, ABCB11 | NPSR1 3942/4885ALDH1A1 3083/4885KMT2A 3993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.